Apellis Pharmaceuticals Inc (APLS NASDAQ) stock market data APIs
$18.2045
-0.18(-1%)
as of July 3, 2025
Try our APIs with
free plan!
Apellis Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Prev. Close
18.2045
Open
18.0225
High
18.2045
Low
17.8977
52 wk Range
16.1-42.47
Market Cap
2 295 M
Shares Outstanding
126 M
Revenue
776 M
EPS
-0.74
Beta
0.669
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apellis Pharmaceuticals Inc data using free add-ons & libraries
Get Apellis Pharmaceuticals Inc Fundamental Data
Apellis Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 776 M
- EBITDA: -184 418 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apellis Pharmaceuticals Inc News
New
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold...
Apellis stock maintains Outperform rating at William Blair on royalty deal
Investing.com - William Blair has reiterated an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS), which has seen its shares decline 46% over the past six months, following the company’s ro...
Apellis signs royalty purchase deal with Sobi for Aspaveli
[Close up blood stream concept] J Studios Apellis Pharmaceuticals (NASDAQ:APLS [https://seekingalpha.com/symbol/APLS]) announced a new agreement with Sobi (SWOBF) (OTCPK:SWOBY [https://seekingalpha.c...
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obliga...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
